Document Detail

β-Blockade: Benefits Beyond Blood Pressure Reduction?
MedLine Citation:
PMID:  22277144     Owner:  NLM     Status:  In-Data-Review    
Hypertension is a major cardiovascular (CV) risk factor, but several other common conditions, including chronic obstructive pulmonary disease (COPD), osteoporosis, and peripheral arterial disease (PAD), have been shown to independently increase the risk of CV events and death. The physiological basis for an increased CV risk in those conditions probably lies in the augmentations of oxidative stress, endothelial dysfunction, systemic inflammation, and arterial stiffness, which all are also hallmarks of hypertension. β-Blockers have been used for the treatment of hypertension for more than 40 years, but a number of meta-analyses have demonstrated that treatment with these agents may be associated with an increased risk of CV events and mortality. However, the majority of primary prevention β-blocker trials employed atenolol, an earlier-generation β(1) -selective blocker whose mechanism of action is based on a reduction of cardiac output. Available evidence suggests that vasodilatory β-blockers may be free of the deleterious effects of atenolol. The purpose of this review is to summarize pathophysiologic mechanisms thought to be responsible for the increased CV risk associated with COPD, osteoporosis, and PAD, and examine the possible benefits of vasodilatory β-blockade in those conditions. Our examination focused on nebivolol, a β(1) -selective agent with vasodilatory effects most likely mediated via β(3) activation.
John R Cockcroft; Michala E Pedersen
Related Documents :
21119534 - Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: e...
7612094 - Hyperthyroidism and seizures during pregnancy.
8898764 - Hypertension in the san antonio heart study and the mexico city diabetes study: sociocu...
11035314 - Should the definition of preeclampsia include a rise in diastolic blood pressure of >/=...
6519754 - Regression of structural cardiovascular changes by antihypertensive therapy.
6334454 - The cardiorespiratory effects of ici 35 868 in patients with valvular heart disease.
Publication Detail:
Type:  Journal Article     Date:  2011-11-11
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  14     ISSN:  1751-7176     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  112-20     Citation Subset:  IM    
Copyright Information:
© 2011 Wiley Periodicals, Inc.
From the Department of Cardiology, University of Cardiff, University Hospital, Cardiff, UK; 1 and the Royal Brompton Hospital, London, UK2.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiplatelet therapy for transient ischemic attack.
Next Document:  The role of nutraceutical supplements in the treatment of dyslipidemia.